
This episode covers the FDA's approval of Biogen's Alzheimer's drug, the implications of remote work policies at major tech companies, and the dynamics of the cryptocurrency community.
The hosts discuss Biogen's Alzheimer's drug, aducanumab, which was recently approved despite its modest efficacy. David Friedberg explains the scientific background and the controversy surrounding the FDA's decision, highlighting the ethical and economic implications of pricing and access to the drug.
The conversation shifts to the return-to-office policies of tech giants like Apple and Google, with the hosts debating the challenges of remote work and its impact on company culture and employee productivity.
In the latter part of the episode, the hosts touch on the Bitcoin conference in Miami, where a culture of toxicity among Bitcoin maximalists is discussed. They analyze how this behavior may affect the broader cryptocurrency community.
Overall, the episode provides insights into healthcare innovation, workplace dynamics, and the evolving landscape of cryptocurrency.
The episode discusses Biogen's Alzheimer's drug approval, remote work policies, and Bitcoin community toxicity.

This episode stands out for the following: